Paediatric drug development and evaluation: Existing challenges and recommendations.

Area of Science:

• Pharmacology and Therapeutics
• Clinical Trial Design
• Regulatory Science

Background:

• Paediatric drug development remains significantly focused on adult indications, leading to unmet medical needs in children and adolescents.
• Challenges include limited trial feasibility, persistent off-label prescribing, and a lack of age-appropriate dosage forms.
• Existing international regulatory initiatives have not fully resolved these long-standing issues.

Purpose of the Study:

• To address the unmet medical needs in paediatric drug development and evaluation.
• To recommend strategies for improving the focus of new drug research and development on children and adolescents.
• To enhance scientific information sharing and cooperation among stakeholders in paediatric research.

Main Methods:

• The panel recommends the establishment of multi-partner exchange forums focused on specific paediatric therapeutic areas.
• Emphasis is placed on leveraging existing French and European paediatric research networks and facilities for clinical trial implementation.
• The study advocates for specific grants, public-private partnerships, and the development of new pharmaceutical forms for paediatric use.

Main Results:

• The proposed forums aim to align drug research with the real unmet medical needs of children and adolescents.
• Enhanced cooperation and data sharing are crucial for defining standardized evaluation methods.
• Increased investment in paediatric drug development is expected through improved pharmaceutical forms and innovation promotion.

Conclusions:

• Multi-partner forums and improved collaboration are essential for advancing paediatric drug development.
• Specific funding mechanisms and public-private partnerships are needed to support crucial pharmacokinetic and drug repositioning studies.
• Creating specialized Ethics Committees (EC) with "mother-child" expertise is recommended to ensure paediatric-specific considerations in medical trials.